ST6Gal-I is upregulated in numerous cancers including ovarian, pancreatic, colon and breast [4–8], and high ST6Gal-I expression correlates with poor patient outcomes in several types of malignancies [5–8]. Here, ST6GAL1 is linked to cancer.